JP2005502579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502579A5 JP2005502579A5 JP2002549247A JP2002549247A JP2005502579A5 JP 2005502579 A5 JP2005502579 A5 JP 2005502579A5 JP 2002549247 A JP2002549247 A JP 2002549247A JP 2002549247 A JP2002549247 A JP 2002549247A JP 2005502579 A5 JP2005502579 A5 JP 2005502579A5
- Authority
- JP
- Japan
- Prior art keywords
- gossypol
- salt
- pharmaceutically acceptable
- prodrug
- acceptable derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims 21
- 238000000034 method Methods 0.000 claims 18
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 229930000755 gossypol Natural products 0.000 claims 6
- 229950005277 gossypol Drugs 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 230000001772 anti-angiogenic effect Effects 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000002889 endothelial cell Anatomy 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- NIOHNDKHQHVLKA-UHFFFAOYSA-N acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde Chemical compound CC(O)=O.CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 NIOHNDKHQHVLKA-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000004548 gossypol derivatives Chemical class 0.000 claims 1
- 230000003862 health status Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25587600P | 2000-12-15 | 2000-12-15 | |
| PCT/US2001/048520 WO2002047673A2 (en) | 2000-12-15 | 2001-12-14 | Methods and compositions to treat conditions associated with neovascularization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502579A JP2005502579A (ja) | 2005-01-27 |
| JP2005502579A5 true JP2005502579A5 (OSRAM) | 2005-05-26 |
Family
ID=22970220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002549247A Pending JP2005502579A (ja) | 2000-12-15 | 2001-12-14 | 新生血管形成に関連する状態を処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6608107B2 (OSRAM) |
| EP (1) | EP1343487A2 (OSRAM) |
| JP (1) | JP2005502579A (OSRAM) |
| CN (1) | CN100490791C (OSRAM) |
| AU (1) | AU2002230888A1 (OSRAM) |
| MY (1) | MY134562A (OSRAM) |
| WO (1) | WO2002047673A2 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385936A (en) | 1990-07-12 | 1995-01-31 | The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services | Gossypol acetic acid for the treatment of cancer |
| CA2417500C (en) | 2000-07-28 | 2008-11-18 | Georgetown University Medical Center | Erbb-2 selective small molecule kinase inhibitors |
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| WO2003038060A2 (en) | 2001-11-01 | 2003-05-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at bcl-2 |
| CN100413493C (zh) * | 2003-06-11 | 2008-08-27 | 中国科学院动物研究所 | 棉酚及其衍生物在制备治疗骨髓瘤药物中的应用 |
| EP1653943B3 (en) * | 2003-06-25 | 2008-07-30 | The Burnham Institute | Catechol derivatives for the treatment of cancer |
| AU2005204685B2 (en) * | 2004-01-07 | 2007-06-21 | E-L Management Corporation | Cosmetic composition and method for retarding hair growth |
| CN1960719B (zh) | 2004-03-25 | 2011-12-07 | 密执安州立大学董事会 | 棉酚共结晶及其应用 |
| US20110091552A1 (en) * | 2007-08-31 | 2011-04-21 | Mccaffrey Tim | Use of Bcl Inhibitors for the Treatment of Scarring Caused By Cutaneous Wounds, Burns and Abrasions |
| JP5406194B2 (ja) * | 2007-10-01 | 2014-02-05 | アセンタ セラピューティックス インコーポレイティッド | Ｒ−ゴシポールｌ−フェニルアラニノールジエナミンを調製するための方法 |
| CN104845532B (zh) | 2009-06-22 | 2017-10-03 | 嘉柏微电子材料股份公司 | 化学机械抛光组合物以及用于抑制多晶硅移除速率的方法 |
| WO2011013846A1 (ja) | 2009-07-29 | 2011-02-03 | 帝人化成株式会社 | ポリカーボネート−ポリジオルガノシロキサン共重合体 |
| CN101810577B (zh) * | 2010-05-06 | 2011-09-07 | 山东大学 | 治疗肿瘤的棉酚静脉注射脂肪乳剂 |
| CN102690326B (zh) * | 2012-05-29 | 2014-04-02 | 武汉大学 | 具有抗艾滋病毒活性的棉酚衍生物及其制备 |
| US9750761B2 (en) * | 2014-05-21 | 2017-09-05 | University Of Rochester | LDH inhibitors as treatment for fibrosis and fibrotic-related disorders |
| US20220162561A1 (en) * | 2019-04-04 | 2022-05-26 | Nissan Chemical Corporation | Composition for promoting secretion of extracellular vesicles |
| CN110559449B (zh) * | 2019-10-22 | 2022-09-02 | 长治医学院 | 一种聚棉酚前药胶束及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260327A (en) * | 1985-10-02 | 1993-11-09 | Sloan-Kettering Institute For Cancer Research | Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine |
| US5026726A (en) * | 1989-12-11 | 1991-06-25 | The University Of New Mexico | Gossylic iminolactones and gossylic lactones and their anti-viral activities |
| US5385936A (en) * | 1990-07-12 | 1995-01-31 | The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services | Gossypol acetic acid for the treatment of cancer |
| US5936120A (en) * | 1997-12-10 | 1999-08-10 | University Of New Mexico | Deoxygossylic compounds |
| US5780675A (en) * | 1995-04-28 | 1998-07-14 | The University Of New Mexico | Deoxygossylic compounds |
| CN1078462C (zh) * | 1997-07-09 | 2002-01-30 | 辛国芳 | 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用 |
-
2001
- 2001-12-14 CN CNB018224156A patent/CN100490791C/zh not_active Expired - Fee Related
- 2001-12-14 JP JP2002549247A patent/JP2005502579A/ja active Pending
- 2001-12-14 AU AU2002230888A patent/AU2002230888A1/en not_active Abandoned
- 2001-12-14 MY MYPI20015730A patent/MY134562A/en unknown
- 2001-12-14 EP EP01991142A patent/EP1343487A2/en not_active Withdrawn
- 2001-12-14 WO PCT/US2001/048520 patent/WO2002047673A2/en not_active Ceased
- 2001-12-14 US US10/020,526 patent/US6608107B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540183A5 (OSRAM) | ||
| JP2010059183A5 (OSRAM) | ||
| JP2017528507A5 (OSRAM) | ||
| Fink | Positioning versus postural drainage | |
| JP2006512324A5 (OSRAM) | ||
| JP2002532392A5 (OSRAM) | ||
| JP2009533356A5 (OSRAM) | ||
| JP2002533390A5 (OSRAM) | ||
| ATE330589T1 (de) | Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege | |
| JP2006526590A5 (OSRAM) | ||
| JP2004527551A5 (OSRAM) | ||
| JP2005508872A5 (OSRAM) | ||
| JP2008510758A5 (OSRAM) | ||
| JP2003519228A5 (OSRAM) | ||
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2017536380A5 (OSRAM) | ||
| JP2023156372A5 (OSRAM) | ||
| JP2023531675A5 (OSRAM) | ||
| JP2023531930A5 (OSRAM) | ||
| Bhat et al. | Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model | |
| JP2005523270A5 (OSRAM) | ||
| JP2009538935A5 (OSRAM) | ||
| JP2008534621A5 (OSRAM) | ||
| Simon et al. | ABI-009, nab-sirolimus, an mTOR inhibitor with high lung accumulation in preclinical models is active in patients with severe pulmonary arterial hypertension | |
| JP2021516757A5 (OSRAM) |